Isosulfan Blue

Manufacturer
Meitheal Pharmaceuticals Inc. | Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Effective date
2021-10-12
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
full-release
Hydrated at
2026-05-31 20:38:17

Label at a glance#

ProductIsosulfan Blue
Active ingredientisosulfan blue
Label structure16 sections

Indications and uses

Isosulfan Blue Injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities.

Dosage and administration

Isosulfan blue injection 1% is to be administered subcutaneously, one-half (1/2) mL into three (3) interdigital spaces of each extremity per study. A maximum dose of 3 mL (30 mg) isosulfan blue is, therefore, injected.

Storage and handling

Isosulfan Blue Injection 1% is a dark blue aqueous solution in a phosphate buffer. It is supplied as follows: NDC Isosulfan Blue Injection 1% Package Factor 71288- 805 -06 50 mg per 5 mL Single-Dose Vial 6 vials per carton Storage  Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Avoid excessive heat. Discard unused portion. Sterile, Nonpyrogenic, Preservative-free. The container closure ...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

1.1 Lymphatic Vessel Delineation

SPL UNCLASSIFIED SECTION

Isosulfan Blue Injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.1 Subcutaneous Administration

SPL UNCLASSIFIED SECTION

Isosulfan blue injection 1% is to be administered subcutaneously, one-half (1/2) mL into three (3) interdigital spaces of each extremity per study. A maximum dose of 3 mL (30 mg) isosulfan blue is, therefore, injected.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

1% aqueous solution (isosulfan blue)

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Isosulfan blue 1% is contraindicated in those individuals with known hypersensitivity to triphenylmethane or related compounds.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Hypersensitivity Reactions

SPL UNCLASSIFIED SECTION

Life-threatening anaphylactic reactions (respiratory distress, shock, angioedema) have occurred after isosulfan blue 1% administration. Reactions are more likely to occur in patients with a history of bronchial asthma, allergies, drug reactions or previous reactions to triphenylmethane dyes. Monitor patients closely for at least 60 minutes after administration of isosulfan blue 1%. Trained personnel should be available to administer emergency care including resuscitation.

5.2 Precipitation of Isosulfan Blue 1% by Lidocaine

SPL UNCLASSIFIED SECTION

The admixture of isosulfan blue 1% (with local anesthetics (i.e. lidocaine)) in the same syringe results in an immediate precipitation of 4–9% drug complex. Use a separate syringe to administer a local anesthetic.

5.3 Interference with Oxygen Saturation and Methemoglobin Measurements

SPL UNCLASSIFIED SECTION

Isosulfan blue 1% interferes with measurements of oxygen saturation in peripheral blood by pulse oximetry and can cause falsely low readings. The interference effect is maximal at 30 minutes and minimal generally by four hours after administration. Arterial blood gas analysis may be needed to verify decreased arterial partial pressure of oxygen.

Isosulfan blue 1% may also cause falsely elevated readings of methemoglobin by arterial blood gas analyzer. Therefore, co-oximetry may be needed to verify methemoglobin level.

6 ADVERSE REACTIONS 

ADVERSE REACTIONS SECTION

6.1 Postmarketing Experience

SPL UNCLASSIFIED SECTION

Hypersensitivity Reactions: Case series report an overall incidence of hypersensitivity reactions in approximately 2% of patients. Life-threatening anaphylactic reactions have occurred. Manifestations include respiratory distress, shock, angioedema, urticaria, pruritus. A death has been reported following administration of a similar compound employed to estimate the depth of a severe burn. Reactions are more likely to occur in patients with a personal or family history of bronchial asthma, significant allergies, drug reactions or previous reactions to triphenylmethane dyes [see Warnings and Precautions (5)].

Laboratory tests: Isosulfan blue 1% interferes with measurements of oxygen saturation by pulse oximetry and of methemoglobin by gas analyzer [see Warnings and Precautions (5)].

Skin: Transient or long-term (tattooing) blue coloration.

7 DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

No drug interactions have been identified with isosulfan blue 1%.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.3 Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when isosulfan blue 1% is administered to a nursing mother.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness of isosulfan blue 1% in children have not been established.

10 OVERDOSAGE

OVERDOSAGE SECTION

Do not exceed indicated recommended dosage as overdosage levels have not been identified for isosulfan blue 1%.

11 DESCRIPTION

DESCRIPTION SECTION

The chemical name of Isosulfan Blue Injection 1% is N-[4-[[4-(diethylamino)phenyl] (2,5- disulfophenyl) methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium hydroxide, inner salt, sodium salt. Its structural formula is:

Structural FormulaStructural Formula

Isosulfan Blue Injection 1% is a sterile aqueous solution for subcutaneous administration. Phosphate buffer in sterile, nonpyrogenic water is added in sufficient quantity to yield a final pH of 6.8 to 7.4. Each mL of solution contains 10 mg isosulfan blue, 6.6 mg dibasic sodium phosphate, anhydrous and 2.7 mg monobasic potassium phosphate. The solution contains no preservative. Isosulfan Blue Injection 1% is a contrast agent for the delineation of lymphatic vessels.

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.2 Pharmacodynamics

PHARMACODYNAMICS SECTION

Following subcutaneous administration, isosulfan blue 1% binds to serum proteins and is picked up by the lymphatic vessels. Thus, the lymphatic vessels are delineated by the blue dye.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

Up to 10% of the subcutaneously administered dose of isosulfan blue 1% is excreted unchanged in the urine in 24 hours in human.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term studies in animals have not been performed to evaluate the carcinogenic potential of isosulfan blue 1%. Reproduction studies in animals have not been conducted and, therefore, it is unknown if a problem concerning mutagenesis or impairment of fertility in either males or females exists.

13.2 Teratogenic Effects

TERATOGENIC EFFECTS SECTION

Pregnancy Category C. Animal reproduction studies have not been conducted with isosulfan blue 1%. It is not known whether isosulfan blue 1% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Isosulfan blue 1% should be given to a pregnant woman only if clearly needed.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

Isosulfan Blue Injection 1% is a dark blue aqueous solution in a phosphate buffer. It is supplied as follows:

NDCIsosulfan Blue Injection 1%Package Factor
71288-805-06 50 mg per 5 mL Single-Dose Vial 6 vials per carton

STORAGE AND HANDLING SECTION

Storage 

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Avoid excessive heat.

Discard unused portion.

Sterile, Nonpyrogenic, Preservative-free.
The container closure is not made with natural rubber latex.

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Inform patients that urine color may be blue for 24 hours following administration of isosulfan blue 1%.

meitheal®
Mfd. for Meitheal Pharmaceuticals
Chicago, IL 60631 (USA)
©2020 Meitheal Pharmaceuticals Inc.

August 2020

810061-00

PRINCIPAL DISPLAY PANEL – Isosulfan Blue Injection 1% 5 mL Vial Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 71288-805-05

Rx Only

Isosulfan Blue Injection 1%

50 mg per 5 mL

(10 mg per mL)

For Lymphography

For Subcutaneous Use Only

5 mL Single-Dose Vial

PRINCIPAL DISPLAY PANEL – Isosulfan Blue Injection 1% 5 mL Vial LabelPRINCIPAL DISPLAY PANEL – Isosulfan Blue Injection 1% 5 mL Vial Label

PRINCIPAL DISPLAY PANEL – Isosulfan Blue Injection 1% 5 mL Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 71288-805-06

Rx Only

Isosulfan Blue Injection 1%

50 mg per 5 mL

(10 mg per mL)

For Lymphography

For Subcutaneous Use Only

6 x 5 mL Single-Dose Vials

Principal Display Panel – Isosulfan Blue Injection 1% 5 mL CartonPrincipal Display Panel – Isosulfan Blue Injection 1% 5 mL Carton

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
4b7700e3-6e0e-45e5-9d22-6f754d61386eProduct name220250304
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
c96fb27b-1a35-b69d-60b2-c2e272527329Product name520231206
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
71288-805-05Isosulfan Blue5 mL in 1 VIAL, SINGLE-DOSEINJECTION, SOLUTION54
71288-805-06Isosulfan Blue6 in 1 CARTONINJECTION, SOLUTION64

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
71288-805ISOSULFAN BLUE INJECTION, SOLUTION [MEITHEAL PHARMACEUTICALS INC.]4Current NDC, Legacy NDC, 2 package rows20211106_d36ae5af-6351-497a-9151-82bcb2c62fa0.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
71288-80571288-805-05, 71288-805-06

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A213130-001ISOSULFAN BLUEISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-03

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A213130-001AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-0384e616aacf4f…
2026-08-18 06:07:402026-07A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-03caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-03011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-0331067a03dcf5…
2025-08-23 18:47 UTC2025-08A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-036a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-03fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-03b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-0303ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-032680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-035bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-03d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-03d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-0379d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-03301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-031e350fbaab3a…
2024-05-31 18:47 UTC2024-05A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-038072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-035c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-035d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-034b0b4de00fa7…
2022-03-09 01:35 UTC2022-03A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-03bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-03782e0a99824c…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-036a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-031c564ffb4f44…
2023-12-20 04:57 UTC2023-12A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-03ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-03a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-039b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-03a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-033f0d92c62455…
2023-05-13 08:27 UTC2023-05A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-03053a50430f4f…
2023-01-26 05:58 UTC2023-01A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-033bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-033a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-03f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-03e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A213130-001ISOSULFAN BLUE1%INJECTABLE / INJECTIONAP2021-11-03cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A213130-001ISOSULFAN BLUE50MG/5ML (10MG/ML)SOLUTION / SUBCUTANEOUSAP2021-11-03a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A213130-001AP184e616aacf4f…
2026-08-18 06:07:402026-07A213130-001AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A213130-001AP1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A213130-001AP131067a03dcf5…
2025-08-23 18:47 UTC2025-08A213130-001AP16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A213130-001AP1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A213130-001AP1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A213130-001AP103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A213130-001AP12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A213130-001AP15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A213130-001AP1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A213130-001AP1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A213130-001AP179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A213130-001AP1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A213130-001AP11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A213130-001AP18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A213130-001AP15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A213130-001AP15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A213130-001AP14b0b4de00fa7…
2022-03-09 01:35 UTC2022-03A213130-001AP1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A213130-001AP1782e0a99824c…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A213130-001AP16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A213130-001AP11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A213130-001AP1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A213130-001AP1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A213130-001AP19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A213130-001AP1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A213130-001AP13f0d92c62455…
2023-05-13 08:27 UTC2023-05A213130-001AP1053a50430f4f…
2023-01-26 05:58 UTC2023-01A213130-001AP13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A213130-001AP13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A213130-001AP1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A213130-001AP1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A213130-001AP1cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A213130-001AP1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Isosulfan BlueISOSULFAN BLUEMeitheal Pharmaceuticals Inc.d36ae5af-6351-497a-9151-82bcb2c62fa02021-10-12Warnings, Adverse reactionsExact identifier
ndc (package): 71288-805-06
ndc (package): 71288-805-05
ndc (product): 71288-805
ndc11 (package): 71288080505
ndc11 (package): 71288080506
spl id: 1c9d3281-9ee0-4e8c-9d36-7736ada64138
spl set id: d36ae5af-6351-497a-9151-82bcb2c62fa0

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.